Key Data From the 2017 Oncology Annual Meeting in Chicago
prIME Clinical Update
prIME Clinical Update

Key Data From the 2017 Oncology Annual Meeting in Chicago

Critical Analysis and Clinical Application

Not a member of My prIME? Join now for instant access.

View CME-certified expert discussions to get the latest updates in oncology and hematology released at the 2017 Oncology Annual Meeting in Chicago. This activity includes critical analysis of the clinical trial data, and discussion on how these data may or should impact clinical practice.

Interactive Presentation

Interactive Presentation

CME

CME

1.5 AMA PRA Category 1 Credits

Release Date

Release Date

Jun 8, 2017

Expiration Date

Jun 8, 2018

ER-Positive Breast Cancer

Featured Experts

  • Kimberly Blackwell, MD, Duke University School of Medicine, Durham, North Carolina, United States
  • Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany

Featured Topics

Abstract #LBA4: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

Abstract #1000: MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

Abstract #1001: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

Abstract #1007: Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO)

Abstract #1038: Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Abstract #1047: First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results

Non-Hodgkin Lymphoma

Featured Experts

  • Loretta Nastoupil, MD, The University of Texas , MD Anderson Cancer Center, Houston, Texas, United States
  • Jeff Sharman, MD, Willamette Valley Cancer Institute/US Oncology Research, Springfield, Oregon, United States

Featured Topics

Abstract #7500: First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study

Abstract #7501:Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study

Abstract #7502: Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL)

Abstract #7519: Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study

Ovarian

Featured Experts

  • Mansoor R. Mirza, MD, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
  • Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, Arizona, United States

Featured Topics

Abstract #5507: Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial

Abstract #5517: Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy

Abstract #5518: Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial

Abstract #5534: Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC)

  • Kimberly Blackwell, MDDuke University School of Medicine
    Durham, North Carolina, United States
  • Wolfgang Janni, MD, PhDUniversity of Ulm
    Ulm, Germany
  • Mansoor R. Mirza, MDCopenhagen University Hospital
    Rigshospitalet
    Copenhagen, Denmark
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St. Joseph's Hospital
    Phoenix, Arizona, United States
  • Loretta Nastoupil, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Jeff Sharman, MDWillamette Valley Cancer Institute/US Oncology Research
    Springfield, Oregon, United States

This educational activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, gynecologists, and other healthcare professionals involved in the treatment of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care

This educational activity is supported by grants from Celgene Corporation, Novartis Oncology, and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Key Data From the 2017 Oncology Annual Meeting in Chicago - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

  • ER-Positive Breast Cancer: 0.5
  • Non-Hodgkin Lymphoma: 0.5
  • Ovarian Cancer: 0.5

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttests are available on the video player pages.

In order to claim credit for these activities, a score of 75% or higher is required on each test.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Blackwell has disclosed that she has received consulting fees from Advaxis, AstraZeneca, Bayer, Celgene, Coherus Biosciences, Eisai, Eli Lilly, Genentech, GI Therapeutics, MacroGenics, Merck, Novartis, Pfizer, Pierian Biosciences, Puma, Roche, Sandoz, and Syndax. She has also performed contracted research via her institution for Celgene, Genentech, Novartis, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Janni has disclosed that he has received honoraria from Amgen, Eisai, GlaxoSmithKline, Novartis Oncology, Pierre Fabre, Roche Pharma AG, and Teva. He has also received research funding from Amgen, Eisai, GlaxoSmithKline, Novartis, Pierre Fabre, Roche Pharma AG, Teva, and Veridex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mirza has disclosed that he has received consulting fees from AstraZeneca, Clovis Oncology, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Monk has disclosed that he has performed contracted research for Amgen, Array, Genentech, Janssen/Johnson & Johnson, Lilly, Morphotek, and Tesaro. He has also received consultation fees from Advaxis, Amgen, AstraZeneca, Bayer, Clovis, Gradalis, Insys, Mateon, Merck, Pfizer, PPD, Roche/Genentech, and Tesaro. He has also received fees for non-CME services received directly from commercial interest from AstraZeneca, Janssen/Johnson & Johnson, Myriad, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nastoupil has disclosed that she has performed contracted research for AbbVie, Celgene, Genentech, Janssen, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Sharman has disclosed that he has received consulting fees from and performed contracted research for AbbVie, Acerta, Celgene, Genentech, Gilead, and TG Therapeutics. He has also received fees for non-CME services from Gilead. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation

The employees of prIME Oncology have disclosed:

  • Elizabeth Cameron, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.